Get Cash Back and $0 Commissions
+ The Power of TradeStation

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Globe Newswire 20-Nov-2023 8:00 AM

BRISBANE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023 at 3:00 p.m. ET.

To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company's two clinical programs, TPST-1120 and TPST-1495, target PPARa and EP2/EP4, respectively, and are advancing through trials designed to study the agents as monotherapies and in combination with approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors 

Aljanae Reynolds
Wheelhouse Life Science Advisors

 If approved by the FDA

Image for Press Release 1803194
Image for Press Release 1803194

Primary Logo